Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study. (September 2020)

• Record Type: Journal Article
• Authors: Pan, Rubing; Zhang, Xulai; Gao, Jiaqi; Yi, Weizhuo; Wei, Qiannan; Su, Hong
• Is Part Of: Psychiatry research. Volume 291(2020)
• Publication Date: 2020-09
• Subjects: Schizophrenia -- Gut microbiome -- Random forest -- 16S rRNA sequencing -- 16S function prediction; Psychiatry -- Periodicals; Psychiatry -- periodicals; Psychiatrie -- Périodiques; 616.89
• DOI: 10.1016/j.psychres.2020.113260
• Languages: English
• ISSNs: 0165-1781

Abstract

Highlights: The Intestinal microbiome plays an important role in the etiology of schizophrenia. The difference in intestinal microbiota between remission and acute schizophrenia suggests that it may be one of the factors affecting the prognosis of the disease. So far, schizophrenia still lacks an objective diagnostic method. Our research s shows that the intestinal microbiota may have good application potential as a non-invasive diagnostic marker. The results show that the intestinal microbiota can provide new ideas for the prognosis and clinical intervention of schizophrenia. Abstract: Exploring the gut microbiota characteristics of patients with acute and remission schizophrenia (SCZ) and evaluating the potential of the gut microbiome as a non-invasive biomarker for SCZ. A total of 87 fecal samples were collected, including a total of 58 samples from 29 SCZ patients over two different periods (remission and onset period) and 29 samples from the control group for 16S rRNA Miseq.The changes of intestinal microbiota in SCZ patients from remission to onset were analyzed, and a random forest model was constructed to recognize biomarkers. The optimal three genus-level diagnosis biomarkers were identified through an AUC validation on a random forest model, furthermore, an AUC of 0.76 (95% CI (0.63, 0.89)) was achieved between 29 aSCZ and 29 HCs. Compared with the control group, the first 11 OUT-level' biomarkers were identified in rSCZ group. As a status marker of the disease, the AUC of 0.7 (95% CI (0.56, 0.84)) was achieved between 29 rSCZ and 29 HCs. There were differences between SCZ patients and HCs, acute and remission patients as well, suggesting that the potential of the gut microbiota as a non-invasive diagnostic tool. Moreover, the features of the gut microbiome of SCZ provide clues for disease prognosis assessment and targeted intervention.